Private Equity

Advantage Solutions overhauls its board, adding heavyweights in capital markets and commercial strategy to navigate a pivotal transformation and retail industry shifts.

With funding from a mining giant, Finlay Minerals' latest results identify three major drill-ready copper-gold targets in BC's Toodoggone district.

With legendary geologist Doug Kirwin and Latin America expert Carlos Velásquez on board, Terra Rossa is set to unlock its high-grade Vetas gold project.

As Evolus presents at a key healthcare conference, investors watch to see if its new filler line and digital strategy can deliver on bold promises.

Investors sue Corcept Therapeutics, claiming the company hid FDA warnings about its key drug, relacorilant, before a 50% stock price collapse.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

As Kimco Realty prepares to present at the Raymond James conference, investors are watching for insights into its grocery-anchored retail strategy.

With its new HAE drug EKTERLY® smashing revenue forecasts, KalVista heads to key conferences where investors will scrutinize its path to profitability.

U.S. Energy Corp. unveils an ambitious plan to merge helium, oil, and carbon capture, but can this small-cap company deliver on its big promises?

The fashion giant's revenue grew 11% in 2025, but net income fell sharply due to acquisition costs, tariffs, and a murky outlook for 2026.

With the appointment of TechTarget co-founder Don Hawk, Life Science Connect is set to import a proven B2B intent data playbook into the life sciences.

The private aviation operator has secured the FAA Diamond Award, signaling a new benchmark in aircraft safety and technician training for the industry.

Fresh off record profits, World Gym details its strategy for global growth, betting on AI health platforms and high-margin services to reshape the industry.

The Swedish health firm reports a 51% revenue surge and record profits, fueled by a string of strategic acquisitions aimed at dominating the Americas.

Insurance giant Kuvare Holdings fires back at inaccurate reports, clarifying its independent oversight in a complex asset management deal with Blue Owl.

The biotech firm secures major funding to push its promising head and neck cancer drug, ficerafusp alfa, toward regulatory approval and commercial launch.

Archrock crushes profit estimates and hikes its dividend, signaling strong confidence as it positions to power the soaring energy demands of LNG and AI.

The life sciences giant's significant dividend hike underscores its robust financial health and commitment to growth, even as it pursues major acquisitions.

Amid market headwinds, Knightvest executed $1.15B in deals and fortified its finances, signaling strong confidence in a 2026 multifamily recovery.

Amid market volatility, Houston's Marble Capital hires Doug Goff to lead a new open-end fund, doubling down on its Sunbelt multifamily strategy.